BUZZ- <a href="https://laohu8.com/S/HRMY">Harmony Biosciences</a> jumps as co announces positive results from sleep disorder drug study** Shares of Harmony Biosciences HRMY.O rise 2.2% to $35.07
** Co reports positive results from key study on pitolisant GR, a gastro-resistant tablet formulation of its sleep disorder drug Wakix designed to withstand stomach acid and dissolve in the intestine
** HRMY says results support plan to file for U.S. approval in early 2026; aims for FDA decision in Q1 2027
** New GR tablets shown to work the same as current Wakix tablets; no new safety issues found
** Study also showed all patients could start at full dose without gradual increase
** HRMY stock up 0.5%% YTD, including session moves
(Reporting by Tharuniyaa Lakshmi in Bengaluru)
((tharuniyaa@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments